PRADI w/ Alix Lacoste

Machine learning model selection and evaluation for target identification

• Selecting machine learning models for drug target identification

• Deep dive into tensor factorization and comparison with other models

• How AI and analytics tools work hand-in-hand with researchers to make informed decisions about novel targets to test in the lab 

Alix Lacoste

VP Data Science, New York Site Lead

Alix has significant experience using data science and machine learning to advance biomedical discoveries. She holds a PhD in Molecular and Cellular Biology from Harvard University. Previously at IBM Watson Health, Alix led computational research projects in target identification and drug repurposing, most notably for Parkinson’s disease and amyotrophic lateral sclerosis, in collaboration with academic and pharma partners. At BenevolentAI, Alix connects AI and Drug Discovery groups to continuously improve the hypothesis generation pipeline.

More Posts

You Might Also Like

BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
Notifications of persons discharging managerial responsabilities
May 5, 2022
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
PDMR Notification (Jean Raby)
May 5, 2022
Notifications of Major Holdings
Apr 29, 2022